MLYS NASDAQ
Mineralys Therapeutics, Inc.
1W: -8.6%
1M: -18.6%
3M: -18.9%
YTD: -33.8%
1Y: -40.6%
3Y: +139.9%
$23.63
-0.09 (-0.38%)
Weekly Expected Move ±9.1%
$19
$21
$24
$26
$28
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (24h)
1
Hourly Sentiment (24h)
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (100)
Mineralys Therapeutics (NASDAQ:MLYS) Stock: Insider Jon Congleton Sells 75,000 Shares
Mineralys Therapeutics (NASDAQ:MLYS) Director Brian Taylor Slingsby Sells 104,320 Shares of Company Stock
Mineralys Therapeutics (NASDAQ:MLYS) Insider Eric Warren Sells 7,438 Shares
Bank of America Corp DE Takes Position in Mineralys Therapeutics, Inc. $MLYS
Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Director Sells $85,740.00 in Stock
Legal & General Group Plc Purchases New Shares in Mineralys Therapeutics, Inc. $MLYS
Greenland Capital Management LP Sells 53,500 Shares of Mineralys Therapeutics, Inc. $MLYS
Bank of New York Mellon Corp Buys New Position in Mineralys Therapeutics, Inc. $MLYS
Understanding the Setup: (MLYS) and Scalable Risk - Stock Traders Daily
Mid-cap healthcare stocks ranked by quant ratings after earnings season
Canada Pension Plan Investment Board Buys New Holdings in Mineralys Therapeutics, Inc. $MLYS
BlackRock Inc. Buys New Position in Mineralys Therapeutics, Inc. $MLYS
Wells Fargo healthcare conference puts Mineralys management on Sept. 9 agenda - stocktitan.net
Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
Mineralys (NASDAQ: MLYS) CCO sells 7,437 shares under 10b5-1 plan - stocktitan.net
HC Wainwright Issues Positive Outlook for MLYS Earnings
Why Mineralys Therapeutics (MLYS) Is Getting Fresh Attention - simplywall.st
Mineralys (NASDAQ: MLYS) insider plans sale after $2,696,321.98 June stock deal - stocktitan.net
Does New CMO Hire and Heavier Leverage Reshape the Bull Case For Mineralys Therapeutics (MLYS)? - simplywall.st
Mineralys (MLYS) Q2 2026 Earnings Call Transcript
Mineralys (MLYS) Q2 2026 Earnings Call Transcript
Mineralys (NASDAQ: MLYS) insider adds 417-share sale to six-figure run - stocktitan.net
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Mineralys' New Chief Medical Officer Receives 4-Year Equity Awards - stocktitan.net
Mineralys Therapeutics (NASDAQ: MLYS) insider files Form 144 to sell 14,056 shares - stocktitan.net
Mineralys Therapeutics (MLYS) CMO exercises options, sells 2,170 shares under plan - stocktitan.net
Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $58,785.30 in Stock - MarketBeat
Mineralys outlines launch readiness ahead of December 22, 2026 PDUFA, with cash runway into 2028
Mineralys Therapeutics Inc (MLYS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and ...
Mineralys Therapeutics, Inc. Q2 2026 Earnings Call Summary
Mineralys Therapeutics, Inc. Q2 2026 Earnings Call Summary
Mineralys Therapeutics Q2 Earnings Call Highlights
Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Why is Mineralys Therapeutics stock sliding today? - Investing.com
MINERALYS THERAPEUTICS ($MLYS) Releases Q2 2026 Earnings - Quiver Quantitative
Mineralys Therapeutics (NASDAQ: MLYS) widens loss but builds $661M cash war chest - Stock Titan
MINERALYS THERAPEUTICS ($MLYS) Releases Q2 2026 Earnings - Quiver Quantitative
Mineralys Therapeutics (MLYS) – David Rodman files Rule 144 for stock sale - stocktitan.net
Mineralys Therapeutics (MLYS) Holds Near $27.38 as Consolidation Persists Between $26.01 Support and $28.75 Resistance - Common Gap - vinanet.vn
Mineralys Therapeutics (MLYS) Heads Into Earnings As Lorundrostat Hopes Meet Undervalued View
Mineralys Therapeutics (MLYS) Heads Into Earnings As Lorundrostat Hopes Meet Undervalued View - Yahoo Finance
Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026
Mineralys Therapeutics (MLYS) Slips 2.56% as Stock Works Within Key Technical Range - Ichimoku Kumo Twist - vinanet.vn
HKEX boosts Bursa Malaysia to Recognised Stock Exchange status - The TRADE
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
A Mineralys Insider Banked a $557,000 Options Gain Before a December FDA Date
What to Know About This Mineralys Insider Sale Before a December FDA Date
A Mineralys Insider Banked a $557,000 Options Gain Before a December FDA Date
What to Know About This Mineralys Insider Sale Before a December FDA Date
Insider Sale: Chief Executive Officer of $MLYS Sells 10,700 Shares - Quiver Quantitative
A $500 Million Funding Deal Could Make Mineralys Therapeutics (MLYS) Stock A Multibagger
A $500 Million Funding Deal Could Make Mineralys Therapeutics (MLYS) Stock A Multibagger - Yahoo Finance
Is Mineralys Therapeutics, Inc. (MLYS) Stock a Biotech Opportunity With Lorundrostat’s Expanding Cardiovascular Potential?
Is Mineralys Therapeutics, Inc. (MLYS) Stock a Biotech Opportunity With Lorundrostat’s Expanding Cardiovascular Potential? - Yahoo Finance
MLYS Forecast — Price Target — Prediction for 2027 - TradingView
What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision
What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision
Mineralys Therapeutics (MLYS) Prices $150M Public Offering of Common Stock
Mineralys: Limited Differentiation Makes Lorundrostat A Weak Competitor - Seeking Alpha
Mineralys Therapeutics (MLYS) Prices $150M Public Offering of Common Stock - Yahoo Finance
Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
Mineralys Therapeutics (MLYS) to Repurchase Potential Royalties for Lorundrostat - Yahoo Finance
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - Yahoo Finance
Biopharma Mineralys joins Goldman Sachs health-care talks in Miami - Stock Titan
Mineralys Therapeutics Stock Plummets 25% With 6-Day Losing Streak - Trefis
Mineralys Therapeutics (MLYS) Shares Encouraging Data for Lorundrostat Clinical Efficacy - Yahoo Finance
12 Health Care Stocks Moving In Wednesday's Intraday Session
Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing
$MLYS stock is down 13% today. Here's what we see in our data. - Quiver Quantitative
Mineralys Therapeutics Prices Underwritten Offering of 5.6 Million Shares at $26.50 Per Share, Expected to Raise $150 Million - Quiver Quantitative
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million - Yahoo Finance
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million - fool.com
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
Trial pill lowers blood pressure, kidney damage marker in CKD - Stock Titan
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
AstraZeneca Scores Key FDA Wins Across Cardiovascular And Oncology Portfolios
Mineralys outlines lorundrostat U.S. launch plans ahead of December 22, 2026 PDUFA
Mineralys (MLYS) Q1 2026 Earnings Transcript
Earnings Scheduled For May 6, 2026
Mineralys Therapeutics GAAP EPS of -$0.47 misses by $0.02
Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
Is Mineralys Therapeutics, Inc. (MLYS) A Good Stock To Buy Now?
Is Mineralys Therapeutics, Inc. (MLYS) A Good Stock To Buy Now? - Yahoo Finance
Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026
David Malcom Rodman Sells 2,170 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Given Average Rating of “Moderate Buy” by Analysts
Mineralys Therapeutics' CEO Sold Shares Worth $1.97 Million. Should Investors Avoid the Stock?
Avalyn Appoints Jon Congleton, Seasoned Biopharmaceutical Executive, to its Board of Directors
Mineralys Therapeutics (NASDAQ:MLYS) CEO Jon Congleton Sells 75,000 Shares
Mineralys Therapeutics (NASDAQ:MLYS) Director Ra Capital Management, L.P. Buys 310,700 Shares
Mineralys Therapeutics Target of Unusually Large Options Trading (NASDAQ:MLYS)
$MLYS stock is up 13% today. Here's what we see in our data. - Quiver Quantitative
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
Hudson Bay Capital Management LP Invests $2.87 Million in Mineralys Therapeutics, Inc. $MLYS